Skip to main content
Advertisement
Live broadcast

Scientists have reported on the association of immune proteins with the risk of prostate cancer

Nature Communications: IL-15 levels linked to lower risk of prostate cancer
0
Photo: TASS/Sergey Karpukhin
Озвучить текст
Select important
On
Off

Men with higher levels of interleukin-15 in their blood were less likely to be diagnosed with prostate cancer more than seven years after sampling. In a combined analysis of two large studies, the relative risk was 14% lower. Scientists have studied whether the immune system can restrain the development of a tumor long before it is detected. For more information, see the Izvestia article.

What was found in the blood before the diagnosis

In the UK, prostate cancer is the most common type of cancer among men. Age, family history, and heredity help assess the risk, but these factors cannot be influenced. The Oxford team turned to another question — whether it is possible to see differences in the functioning of the immune system in people who have not yet been diagnosed.

As part of the EPIC European study, scientists studied 368 proteins associated with the immune response and inflammation. They compared blood samples from 1,434 men who were subsequently diagnosed with prostate cancer with samples from 1,434 comparable participants in the control group.

On average, more than ten years passed between blood collection and diagnosis. The researchers then compared the results with data from the British Biobank, where 1,147 cases of the disease were registered among 21,481 men.

When checking hundreds of proteins, some connections may appear by chance, so the scientists adjusted for the number of comparisons. When analyzing all the cases in the European sample, not a single link stood up to such a test. The picture changed after combining the data and taking into account the time elapsed before the diagnosis.

When the scientists looked at cases identified more than seven years later, they found six proteins, higher levels of which were associated with lower risk. These include interleukin-15 (IL-15) and the ligand FLT3 (FLT3LG), which is involved in the development of immune cells.

Why did researchers isolate interleukin-15?

Interleukin-15 supports the work of T-lymphocytes and natural killer cells, or NK cells. These cells are able to recognize and destroy some of the body's altered cells. According to the authors, this work of the immune system, which is called immune surveillance, may be important in the early stages of tumor development.

"We usually study the immune system when there is already a tumor," said Mahbube Parsayan, lead author of the study and senior medical statistician at Oxford University.

According to her, data on proteins in the blood before diagnosis allows us to study the role of the immune response at the onset of the disease.

Information about the stage of the tumor was available in the EPIC sample. There, higher levels of IL-15 were also associated with a 26% lower chance of being diagnosed with advanced prostate cancer. This is a preliminary assessment. When analyzing the stages, the relationship did not retain statistical significance after adjusting for the number of tested proteins.

Why did scientists study an enzyme that is already affected by drugs?

In the genetic part of the work, scientists have isolated PARP1, an enzyme that is involved in repairing damaged DNA. In the British Biobank, a genetically predicted higher level of PARP1 was associated with an increased chance of developing prostate cancer. The result was repeated in a combined analysis of an independent sample that included men of different backgrounds.

This enzyme is already affected by some anticancer drugs. Genetic analysis reflects differences that can operate throughout life. The efficacy and safety of using such drugs for prevention would need to be checked separately.

As part of the Prostate Cancer Aetiology and Prevention (PCAP) program, researchers intend to find out how these proteins interact and whether it is possible to reduce the risk of the disease by influencing them. To do this, it is important to understand in what period before the development of the tumor such an intervention could make sense and to whom it could benefit.

Переведено сервисом «Яндекс Переводчик»

Live broadcast